Cytek Biosciences, Inc. (CTKB) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Thanks, operator. With me on today's call from Cytek are CEO Wenbin Jiang and CFO Bill McCombe. Cytek Biosciences put out its financial results earlier today for the second quarter, which closed on June 30th, 2026. Should you not have gotten that news release, or if you want to join the company's distribution list, just email investors@cytekbio.com. You can also find a copy of the release in the investor relations area of Cytek's site, investors.cytekbio.com. Keep in mind that during today's call we'll be referencing the slide presentation that's been posted in the investor section of our corporate website. As a reminder, on Slide 2, some of what we say today will be forward-looking statements under the Federal Securities laws, and that covers things like Cytek's business plans, strategies, opportunities, and financial projections; such statements rest on the company's current expectations and come with significant risks and uncertainties by their nature, which might cause actual results or events to differ materially from what those statements anticipate. You can find additional information about these risks and uncertainties in our slide presentation, under the section titled Forward-Looking Statements in the press release Cytek issued today, and in Cytek's filings with the SEC. Today's call will also touch on certain financial measures not calculated in accordance with generally accepted accounting principles. Additional information about our use of non-GAAP financial measures, including reconciliations to the most directly comparable GAAP financial measures, is available in our slide presentation and in today's press release. Although the company believes these non-GAAP financial measures give investors useful information, presenting this information is not meant to be considered on its own or as a replacement for the financial information presented in accordance with GAAP. Except as required by law, Cytek disclaims any duty to update any forward-looking statements, whether due to new information, future events, or changes in its expectations. This conference call contains time-sensitive information and is accurate only as of the live broadcast on August 5th, 2026. Last, I want to remind everyone about the organizational update we mentioned on our prior call. In the third quarter of 2026, Cytek will start operating as three distinct customer-aligned business units: Solutions and Clinical, Research Technology, and Service. For more details about these business units, please see the slide included in the appendix of our presentation. With that, I'll hand the call over to Wenbin.
Thank you, Mark. I'd like to welcome all of you, and we appreciate your interest in Cytek. During this call, I'll begin by talking about how we performed in Q2 and point out a few exciting new product introductions, then I'll hand things over to Bill, who will walk through our financials in detail along with our revised outlook for the full year. Moving to slide 3. We followed up our solid beginning to the year with ongoing favorable momentum during the second quarter, posting yet another stretch of healthy revenue growth. Revenue for the second quarter of 2026 came in at $48.1 million, which is 6% higher than the same period last year. Several factors powered our Q2 results: robust double-digit revenue gains in the U.S. and China, improved mix from our FSP instruments, and steady double-digit expansion in our service business. Now to slide 4. Looking at regions, in the United States, Q2 revenue reached $28.2 million, up 18% compared with a year earlier. That extends the powerful trend we saw in Q1 and mirrors notable increases in instrument revenue within the academic and government sector as well as in our service business. In EMEA, revenue for the second quarter totaled $11.3 million, roughly 8% lower than the prior-year period, which mirrors ongoing budget constraints stemming from regional geopolitical developments. APAC revenue overall, China included, amounted to $7.9 million, unchanged from a year ago. China posted strong double-digit growth against an easy year-on-year comparison, but weakness elsewhere in the region offset that gain. Moving on to slide 5. We kept growing our worldwide footprint during Q2, adding 142 units, which lifted Cytek's total installed base to 3,933 units. We once again saw healthy instrument unit growth in the second quarter, powered by our high-end FSP instrument portfolio, which rose 11% versus a year earlier and was paced by the Aurora Evo Analyzer and Aurora CS Cell Sorter. Now to slides 6 and 7. I'd also like to call attention to two exciting new product introductions that further broaden our technology leadership and lay the groundwork for our next stage of growth. To start, we recently unveiled the Cytek Borealis, which is the industry's first 60-color, seven-laser, full spectral-flow cytometer. Reaching the ability to resolve 60 unique colors within one sample run became possible through Borealis' distinctive technology, in which seven lasers fire at the same time alongside purpose-built and proprietary deep UV and IR dye reagents. Being able to analyze 60 colors in one run greatly widens the range of cellular biomarkers scientists can assess while preserving the direct hierarchy comparison advantages of a single-tube sample. Beyond the technological advantages that boost analytical capability, Borealis additionally provides greater efficiency for our customers, among them the capacity to analyze nanoparticles, which broadens the variety of sample types, high flow rates that raise the pace of analysis and the system's throughput, and improved automation that removes the requirement for manual sample handling. The Borealis system has likewise been engineered to permit the integration of onboard high-parameter cellular imaging capabilities. Adding imaging together with sophisticated full spectrum detection using seven lasers means Borealis can deliver a richer cellular picture from just one sample, which marks yet another important advance in what our clients are able to discover from each run. The response we've gotten from customers in our early access program has been extremely positive, and we're eager to reveal additional details about Borealis as we move closer to broader commercial release. Next, we rolled out the fresh Aurora Evo instrument configurations, which come with greater automation. Thanks to these improvements, full spectral-flow cytometry can now be brought into heavily automated lab settings through the addition of automated and remote control of essential instrument operations, plus an API that connects with automated plate handling systems, removing any requirement for a person to operate the equipment. Such features matter greatly for biopharma companies and CROs, since efficiency, reproducibility, and system integration are essential for large-scale initiatives. All together, these recently introduced offerings highlight our ongoing dedication to broadening our technological lead while supporting pioneering research and boosting lab output for those we serve. Now shifting to Applications and Service. Our recurring revenue foundation kept getting stronger during the second quarter. Reagents and service revenue combined reached $18.5 million in Q2 2026, a rise of 8% compared with the same period last year, making up 35% of Cytek's revenue over the last 12 months, an increase from 32% for the 12 months ending June the 30th, 2025. Service revenue came to $15.6 million during the second quarter, climbing 10% year-over-year, fueled by ongoing expansion of our installed base and heavy use of our instruments among customers around the globe; we anticipate that recurring revenue will account for a growing share of our overall revenue as time goes on, backed by strong utilization and the ongoing growth of our installed base. Shifting to bioinformatics. Cytek Cloud remains essential for researchers striving to build and refine experimental workflows, and it also fuels uptake and usage of our cell analysis offerings. As of June the 30th, 2026, Cytek Cloud has gone beyond 28,000 users, a 15% increase since the beginning of the year. Rising numbers of Cytek Cloud users highlight the power of our connected ecosystem and foster deeper involvement from customers. We think this growing engagement serves as a key driver of growth for our reagent and service operations; with that, I'll hand the call over to Bill now for further information about our Q2 financial results and our revised guidance.
Thanks for that, Wenbin. Let's turn to slide 8. In the second quarter, we brought in $48.1 million in revenue, an increase of 6% compared with the $45.6 million recorded in Q2 2025. This improvement came largely from strong results in the U.S., where we saw 18% growth versus the prior year and our best-ever Q2 revenue, plus solid expansion in China. Those positives were partially counterbalanced by continued weakness across EMEA and the rest of APAC outside China. Instruments and reagents together made up product revenue of $32.6 million, a 4% rise year over year, powered by our high-end instrument sales, which posted mid-teens growth in Q2; we also noticed improved sentiment and significant revenue gains among academic and government clients in the U.S. At the same time, we saw expansion among biopharma distributor and CRO accounts in various geographies. Instrument sales in EMEA declined by 10% compared with the same period last year, which mirrors the budget constraints Wenbin discussed previously. Product revenue in APAC outside of China also came in lower, attributed to typical ups and downs in buying behavior after a robust first quarter. Service revenue reached $15.6 million, up 10% versus a year ago, fueled by our growing installed base and strong instrument usage around the world. Turning to customer segment, biopharma distributor and CRO revenue climbed roughly 22% year-over-year to $29 million, reflecting robust gains in EMEA and China. Academic and government revenue totaled $19.1 million, a decline of about 12% from the prior-year period. U.S. academic and government revenue posted strong growth relative to both last year's Q2 and this year's Q1. The gains there were counterbalanced by softer performance from schools and public agencies in EMEA, along with the rest of APAC outside China, following a robust first quarter in each of those areas. Moving on to slide 9. On a GAAP basis, gross profit for Q2 came to $28.3 million, a 59% gross margin, and that figure reflects a $2.8 million tariff refund that occurred just once during the quarter. If you set aside the tariff refund, gross margin lands at 53%, versus 52% in Q2 2025. Product gross margin stood at 60%, or 52% once the tariff refund is excluded, compared with 53% in the same quarter last year. Service gross margin reached 56%, an increase over 52% in Q2 2025, driven by reduced material costs. When we strip out stock-based compensation along with amortization tied to acquisition intangibles, adjusted gross margin landed at 61% for the second quarter. If you also back out the tariff refund, that figure comes to 56%, whereas the same period a year earlier stood at 56%. Looking ahead to the remaining quarters of this year, we anticipate that gross margins—setting aside the tariff refund's effect—will rise, since our revenue growth should track our usual seasonal rhythm. Operating expenses for Q2 totaled $39.7 million, marking a 15% increase over the second quarter of 2025. Research and Development came in at $9.7 million, a 10% gain compared with Q2 2025, driven mainly by greater personnel costs. Sales and Marketing reached $13.2 million, up 9% from Q2 2025, largely on the back of higher personnel costs plus advertising and marketing spending. G&A costs reached $16.8 million, which is a $3.3 million jump, or 24%. This rise largely came from increased legal fees tied to the patent litigation matter we've already told you about, plus bigger severance and other people-related expenses. Our operating loss for the quarter that just closed was $11.4 million, compared with $10.6 million in the same quarter last year. GAAP net loss for Q2 came in at $12.2 million, versus $5.6 million in the prior-year comparable quarter. That wider GAAP net loss had three causes. Number one: an operating loss that was larger by $0.8 million. The second was net other income that came in $4.5 million lower, largely reflecting foreign exchange losses of $0.7 million this quarter against $1.6 million of gains a year ago, plus a $1.6 million non-recurring write-off tied to an investment in an early-stage technology company. And the third was tax expense of $0.5 million this quarter, versus a tax benefit of $1.2 million in the year ago period. Adjusted EBITDA, which leaves out stock-based compensation, foreign exchange impacts, and that non-recurring write-off, showed a loss of $1.5 million in Q2 2026, versus a positive $1.3 million in Q2 2025. That Adjusted EBITDA loss stemmed mainly from the larger operating loss, a smaller add back of stock-based comp, and reduced investment income. Even so, we expect Adjusted EBITDA to get better during the second half, as revenue climbs along with our usual seasonal pattern and operating expense growth slows. For the whole of 2026, we're looking to deliver Adjusted EBITDA around breakeven. Free cash flow in the quarter was roughly neutral. As of June 30, 2026, cash, cash equivalents, and marketable securities came to $262 million, versus $262.2 million as of March 31, 2026. Our solid balance sheet keeps giving us the financial flexibility to put money into our global growth priorities. Moving to slide 10. Starting today, we are raising the lower bound of our revenue outlook for the entire 2026 fiscal year. The updated range now stands at $207 million to $212 million, which lifts the midpoint by $1 million. This assumes no movement in foreign exchange rates. The revised view reflects the strong performance we have seen thus far this year, along with the more favorable growth picture across the markets we serve, particularly the U.S. and APAC, including China. Looking at the back half of the year, we anticipate that fourth quarter revenue will land well ahead of the third quarter, consistent with the seasonal revenue trends we normally see. With that, I'll turn things back over to Wenbin.
Appreciate it, Bill. Moving on to slide 11. To wrap things up, I'd like to express gratitude to each member of the Cytek team for the ongoing commitment and execution they deliver on behalf of our stakeholders. The results from our second quarter and first half demonstrate how strong our technology leadership is within the flow cytometry industry. In Q2, revenue rose 6% compared to the same period a year earlier, reaching $48.1 million, and momentum in the U.S. and China shows the appetite for what we've built. Recurring revenue now accounts for 35% of revenue over the trailing 12 months, with service revenue posting steady double-digit growth versus the prior year, and our related business continues to be well-positioned for expansion. As we look forward, our priorities haven't changed. Speeding up market penetration for our instrument platforms, which includes the recently introduced Borealis and Aurora Evo automation capabilities, pushing our technological leadership forward via ongoing innovation, growing our recurring revenue line, and achieving profitable, sustainable growth; we feel the investments made in our products, our people, and our operations put Cytek in a strong position for fundamental operational success and for the considerable long-term opportunity that lies ahead. Thank you all for being on today's call. We're now ready to take questions. Operator?
Thanks a lot for fielding our questions, folks. We really value the detail you provided regarding the geographic and end market split this quarter, particularly for China and the EU. Given that the funding picture for biotech keeps getting better, is it fair to anticipate that expansion will start to even out across the different end markets? Also, how would you suggest we view the various options you have available to take advantage of the rebound in the U.S. compared with these other regions? Any insight into how much each area is contributing would be much appreciated. Thanks.
Hello, Brendan, Bill here. Demand was robust and momentum was strong within the U.S., primarily fueled by academic and government clients. U.S. biopharma. It came in fairly level overall. During the first six months, though, U.S. Biopharma grew at roughly a 20% clip, which means it's still delivering solid expansion when you look at a longer time frame. In Europe, conditions remained difficult. Our observation is that government money for R&D keeps facing downward pressure, driven by changing spending priorities in that region and a focus on other sectors like defense. China performed really well this quarter, while the rest of APAC saw a somewhat weaker quarter. Even so, we anticipate that over the longer haul, the region overall will remain a robust growth market. When it comes to the levers we can pull, there are major new offerings we've already discussed — Borealis, along with Aurora Evo automation featuring improved automation — and customer interest in these has been extremely strong. We're also continuing to put money into our sales and marketing organization. Our brand carries a lot of weight and stands for the top technology in this field, and that holds true across every major market.
Beyond that, what we've observed is that orders for Cytek products keep showing outstanding results, are extremely well received by the people we serve, and are turning into the true everyday instrument for their routine uses.
Okay, that sounds good. Thank you, everyone. I appreciate that.
Hello, this is Skye filling in for Dave. I appreciate you taking the question. To start, I believe previously you mentioned that globally there are 46,000 flow cytometers installed, representing a long-term opportunity for replacement. Is there any insight you can provide regarding the real yearly rate at which those instruments are replaced or retired? Could you also discuss the instrument placements made recently — were those competitive upgrades away from conventional systems, or are they purely net new full spectrum adoption, or expansion occurring inside accounts that already use full spectrum? After that, I have one more question. Thanks.
According to the market report, placements each year fall in the 7,000 to 10,000 range, so within that band. As far as Cytek goes, we compete mainly at the high end of the research market, inside that particular segment, and we keep witnessing strong traction for our products. There is an increasing shift among customers toward full spectral technology, where we have performed better within our space; we think we are still gaining share in that regard.
All right, that's helpful, thank you. And for my second question, could you share a little more about what's happening in China? I recall you've previously named China as one of the clinical markets where you're growing. You had double-digit growth there this quarter. When it comes to how Chinese clinical flow cytometry is being adopted, what are you observing, and how does that compare with the core academic and government segments? Thanks.
As you're aware, our Northern Lights-CLC does hold clinical approval for hospital use in that country. Much like what happens with numerous applications in other regions, actually, our research instrument remains the biggest contributor to our sales in that market. And if you look at all the public datas out there, Cytek is still among the top three players in the China market.
I'd like to make one more point tied to that earlier question regarding the replacement opportunity. When you examine the metrics our competitors have put out in their releases, and then you set those against our growth rate, ours comes out looking considerably stronger than theirs. A factor that might explain this is the swapping out of conventional flow cytometers for FSP, along with, clearly, the power of our technology and the standing of our brand. My sense is that how our growth rate stacks up against the peers would confirm that this replacement opportunity is a dynamic benefiting us.
Hello, Jason here, filling in for Kallum. Thanks for letting us ask questions. I suppose I have one about the strategic reorganization, the one meant to establish new business units and line up resources so growth gets driven. Could you bring us up to date on where things stand operationally with that reorganization, and what still has to happen before it wraps up in 3Q? How quickly might we see the advantages of this initiative flow through to the P&L? Might those advantages begin appearing in Q4, and if so, would that be additional upside relative to the 2026 guide? And what about the chance of disruption for customers, whether from shifts in the sales force or from other causes? Thanks.
That implementation is underway right now. Like we told you, Q3 was when we intended to put it in place, and we've begun doing so. When it comes to the main aim behind this restructuring, I'd say it's about getting resources lined up with each of our distinct customer segments. Once that happens, our expectation is that it lifts our growth rate and especially strengthens our market penetration in mid and low-end instruments along with reagents. That territory falls under the Solutions business. Well, meaningful results from this will require some time to materialize. The guidance we provided for this year captures the, or rather presumes that this implementation is taking place currently and will keep going. It's incorporated into the guide. Those, I think, are the key points.
My view is that the way we've organized things will actually let us take better care of our customers, since each product targets a distinct customer segment. This lets us truly concentrate our resources, our marketing, and our R&D so we can best tune our products and our marketing message toward what our customers need. We don't anticipate any disruption. Actually, it ought to improve how we serve our customer.
The main advantage is going to appear as a better top-line growth rate, better market penetration in the solutions markets, and a generally better top-line growth rate; it will take some time to appear because those efforts are essentially only starting. As time goes on, we believe this organization will substantially improve our growth rate.
Thanks. To build on what was just said, I believe the slides noted that a clinical-focused unit is among the three new business units. They point out that Cytek holds a small share of the clinical market at present, and that this market offers substantial room to grow. In your view, why is flow cytometry still under-penetrated in clinical settings these days, and what approach will Cytek take to break into the clinical market? Thank you.
The unit is in fact named the Solutions and Clinical business unit, since clinical forms one piece of the solutions. Broadly speaking, if you examine the pure side, clinical breaks into 2 parts. The first is true clinical diagnostics, that segment of the business. The second is more of a research-oriented, clinical-directed business; we currently serve both markets, and with what we have built, especially the panels, reagents, and the software improvements that drive application and deeper reach into that market throughout all territories, such as China, Europe, and the U.S.
Yeah. See, the reason this is only a modest business for us at present is that we've got the green light for the clinical product across EMEA and Asia, yet we lack that clearance in the U.S. That's among the factors behind our current small footprint — along with the room to expand substantially down the road.
Thanks for the responses. Nice work on the quarter.
Thanks.
Hi there, Harrison here, filling in for Mason. I appreciate you taking my questions. I wanted to ask whether the assumptions regarding instruments, service, and reagents that went into the guide have changed in any way. Last quarter, our expectations were that services and reagent revenue would keep growing at levels in line with recent quarters, while instruments would see flat to modest growth. Within the updated guidance framework as it stands today, does that same framework still apply?
Yes, by and large, that holds true. Look, each quarter we review the results and make adjustments to the framework. Our service business was up 10%. We'd anticipate services continuing to grow at that rate or better. I don't think there are any major changes. Instrument revenues, honestly, came in a bit toward the upper end of the range of assumptions we had. We examine the quarter and look at a variety of scenarios, and then we build the range by evaluating a set of scenarios. I'd say that framework hasn't seen significant changes.
Understood. Back when you first put the guidance together in February, you mentioned a cushion included for unexpected macroeconomic events. Has any portion of that cushion already been used up during the first half? And if that cushion is still baked into the guidance, what dollar amount does it represent for the back half?
Yeah. Look, some contingency does exist there. We don't disclose it separately. There isn't a single formula with particular figures that we apply to generate the guide. It isn't a formulaic or mechanical computation. We examine multiple scenarios. Some contingency remains in the back half. You'll observe that growth in the first half came in faster than what would be implied, certainly by the low end of our guide, and even the midpoint of the guide. From that, you can draw the conclusion that we still hold some contingency within our number; we aren't projecting any shift in our markets.
Great. Thanks for taking the questions.
That wraps up the Q&A portion. Everyone, we appreciate your participation in today's call. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytek Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Cytek Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.